tbuckley/cabot-search huggingface dataset:
A New Pronouncing Dictionary of Medicine.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Roentgen Diagnosis of Rheumatoid Arthritis.
Authors: David L. Berens, Ru-Kan Lin
Journal: Annals of Internal Medicine (1970)

The authors have endeavored to assemble the nonlaboratory methods of examination and the principal diagnostic findings of all branches of medicine except obstetrics and pediatrics. The result is far superior to any other textbook of physical diagnosis. It begins with a wise discussion to define diagnosis, and then describes the procedures of physical examination, correlating observations with their clinicopathologic interpretation. The arrangement is largely by systems with the exception of a section in which diseases are listed alphabetically together with a few outstanding signs of each. The numer-
Methods and Approaches for Assessing Immunotoxicity: An Overview
Authors: Jack H. Dean, Michael I. Luster, Gary A. Boorman
Journal: Environmental Health Perspectives (1982)

The goals of the National Toxicology Program as they relate to immunological evaluation in toxicity assessment are discussed. The advantages of immune function assays for defining cellular injury as subtoxic levels following exposure to general or immunocyte specific chemical toxicants are proposed. A comprehensive screening panel of immune function and host resistance assays is presented in the context of an NIEHS approach for immunotoxicity assessment and methods selection. A second panel for defining the mechanism underlying immunological injury was also described. Studies utilizing these methods and approaches are described in companion papers by our group.
EXTH-34. PHASE I TRIAL OF CONVECTION-ENHANCED DELIVERY OF IL13RA2 AND EPHA2 RECEPTOR TARGETED CYTOTOXINS IN DOGS WITH SPONTANEOUS INTRACRANIAL GLIOMAS
Authors: John Rossmeisl, Denise Herpai, Ralph D’Agostino, John Rossmeisl, Stephen Tatter, Peter Dickinson, Waldemar Debinski
Journal: Neuro-Oncology (2020)

Abstract The interleukin 13 receptor alpha 2 (IL13RA2) and ephrin type-A receptor 2 (EPHA2) receptors are attractive therapeutic targets, being expressed in ~90% of canine and human gliomas, and absent in normal brain. Clinical trials using an earlier generation IL-13 based cytotoxin showed encouraging clinical effects in human glioma, but met with technical barriers associated with the convection enhanced delivery (CED) method. In this study, IL-13 mutant and Ephrin-A1 (EFNA1)-based bacterial cytotoxins targeted to IL13RA2 and EPHA2 receptors, respectively, were administered locoregionally by CED to dogs with intracranial gliomas to evaluate their safety and preliminary efficacy. In this Phase I, 3 + 3 dose escalation trial, cytotoxins were infused by CED in 17 dogs with gliomas expressing IL13RA2 or EPHA2 receptors. CED was performed using a shape-fitting therapeutic planning algorithm, reflux-preventing catheters, and real-time intraoperative MRI-monitoring. The primary end point was to determine the maximum tolerated dose of the cytotoxic cocktail in dogs with gliomas. Consistent intratumoral delivery of the cytotoxic cocktail was achieved, with a median target coverage of 70% (range, 40–94%). Cytotoxins were well tolerated over a dose range of 0.012–1.278 mg/mL delivered to the target volume (median, 0.099 mg/mL), with no dose limiting toxicities observed. Objective tumor responses, up to 94% tumor volume reduction, were observed in 50% (8/16) of dogs, including at least one dog in each dosing cohort &amp;gt;0.05 mg/mL. This study provides pre-clinical data fundamental to the translation of this multi-receptor targeted therapeutic approach to the human clinic.
The Title of Physician: Who is a Physician, and Who Has the Right to Call Himself by that Title?
Journal: BMJ (1895)

aols, poorhouses, lunatic asylums, and similar institutions.In future the possibility of the case being of this nature must be borne in mind by the Australian practitioner when he ap- *proaches the diagnosis of peripheral neuritis.Dr. Corlette's remarks on treatment are judicious; he very properly dwells on the paramount importance of removal of the patient from the endemic locality.He says nothing.however, about the employment of bleeding, nitrite of amyl or nitroglycerine and purgatives, measures which have been found of service elsewhere in relieving the attacks of orthopncea from overdistended right heart, so common and so dangerous an occurrence in bad cases of beri-beri.The sanitary authorities in Australian towns will doubtless take note of the appearance of beri-beri in the colonies, and institute measures calculated to improve the hygienic condi- tions under which their fellow Chinese colonists elect to live.
Practices and Attitudes of Japanese Oncologists and Palliative Care Physicians Concerning Terminal Sedation: A Nationwide Survey
Authors: Tatsuya Morita, Tatsuo Akechi, Yuriko Sugawara, Satoshi Chihara, Yosuke Uchitomi
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To clarify the frequency of practice of sedation therapy for terminally ill cancer patients and to identify physicians’ attitudes toward sedation. METHODS: Questionnaires were mailed to 1,436 Japanese oncologists and palliative care physicians with a request to report their practice of and attitudes toward palliative sedation therapy. RESULTS: A total of 697 physicians returned questionnaires (response rate, 49.6%). Use of mild, intermittent-deep, or continuous-deep sedation for physical and psychologic distress was reported by 89% and 64%, 70% and 46%, and 66% and 38%, respectively. In vignettes in which physicians were asked whether they would use sedation for a patient with refractory dyspnea or with existential distress, 14% and 15%, respectively, chose continuous-deep sedation as a strong possibility. Those physicians less confident with psychologic care and with higher levels of professional burnout were more likely to choose continuous-deep sedation. In vignettes in which they were asked whether they use sedation for a patient with depression or delirium, 39% and 31%, respectively, considered psychiatric treatment to be a strong possibility, and 42% and 50% regarded continuous-deep sedation as a potential treatment option. Physicians less involved in caring for the terminally ill and less specialized in palliative medicine were significantly less likely to choose psychiatric treatment. CONCLUSION: Sedation is frequently used for severe physical and psychologic distress of cancer patients. Physicians’ clinical experiences with the terminally ill and their levels of professional burnout influence the decisions. Training and education for physicians in regard to end-of-life care and valid clinical guidelines for palliative sedation therapy are necessary.
Ocular Thermal Effects Produced by Photocoagulation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immune boosters disappoint AIDS researchers
Authors: P. Cotton
Journal: JAMA (1991)

TRYING TO REBUILD the immune system with drug therapy has been one of the more disappointing areas of research into treatment of acquired immunodeficiency syndrome (AIDS). Trials "have either shown no evidence of immune reconstitution with laboratory parameters, or differences in clinical end points we are hard pressed to explain," says Robert T. Schooley, MD, professor of medicine and chief of infectious diseases, University of Colorado Health Sciences Center, Denver, and chair of the National Institutes of Allergy and Infectious Diseases AIDS Clinical Trials Group immune-based therapies study group. Whether small improvements in immune parameters that are seen with some agents are clinically relevant is hard to tell, adds Schooley. "We know a lot about human immunodeficiency virus [HIV] immune-specific responses, but we don't know enough about what aspects of that response are protective yet. We're a long way away from having enough sophistication about what we're measuring to do
Book Received
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pancreatitis
Authors: Lee R. Sataline
Journal: JAMA (1968)

<h3>To the Editor:—</h3> In their paper on use of hypothermia in the management of acute pancreatitis (<b>201</b>:825, 1967) Roddenberry and Conger report two cases in which there are several objectionable aspects in the diagnosis and treatment. While pancreatitis secondary to trauma could be suspected in case 1, the fact that the serum amylase level just prior to discharge was 200 units higher than on admission mitigates against such a diagnosis. Therefore, the value of hypothermia in the management of this patient cannot be properly evaluated. Furthermore, the use of such a potentially dangerous drug as chloramphenicol without overt infection must be reproved. In case 2, surgery was not indicated. The preoperative diagnosis of recurrent appendicitis especially as a cause of abdominal pain in an alcoholic is untenable. Again, the postoperative use of chloramphenicol in addition to a penicillin-streptomycin mixture (Strep-Combiotic) was unwarranted and contrary to the advice of most
Correspondence
Authors: C. Pincelli, G. Girolomoni, L. Benassi
Journal: British Journal of Dermatology (1986)

Journal Article Correspondence Get access C. Pincelli, C. Pincelli Department of Dermatology, University of Modena, 41 100 Modena, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Girolomoni, G. Girolomoni Department of Dermatology, University of Modena, 41 100 Modena, Italy Search for other works by this author on: Oxford Academic Google Scholar L. Benassi L. Benassi Department of Dermatology, University of Modena, 41 100 Modena, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 115, Issue 4, 1 October 1986, Pages 512–513, https://doi.org/10.1111/j.1365-2133.1986.tb06249.x Published: 01 October 1986
HINTS FOR DIAGNOSIS OF DISEASE OF GALLBLADDER AND OF BILIARY PASSAGES
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beginnings of bronchitis.
Authors: T Halil
Journal: BMJ (1970)

used in oral contraceptives, ethinyloestradiol and mestranol, at doses of 50 pg.and 100 pg., did not show any constant difference in risk for the United Kingdom figures, but the numbers available for analysis were small.It was also possible to obtain some evidence that the progestogen component may affect the incidence of thromboembolism.Thus at the 100 ,ug.dose of mestranol there were fewer reports of thromboembolism in each diagnostic group with 2-5 mg.norethynodrel than with other types of progestogen, and a significant excess of reports of venous but not arterial thromboembolism at the 50 ,ug.dose of ethinyloestradiol when combined with 4 mg.megestrol.Such results are particularly difficult to explain because norethynodrel is believed to have oestrogenic effects in animals while megestrol is thought to be without oestrogenic activity.A further discrepancy is the excess of reports at the 50 pg.dose of mestranol as compared with the 75 or 80 pig.dose, which might also be due to the progestogen.
Traité des maladies de la prostate.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recommendations for the Prevention of Malaria Among Travelers
Journal: JAMA (1990)

Recommendations for the prevention of malaria among travelers have been developed by CDC in consultation with representatives from the Offices of Medical Services of the Department of State and the Peace Corps; the Division of Experimental Therapeutics of the Walter Reed Army Institute of Research; the Office of the Surgeon General, U.S. Army; the Office of the Surgeon General, U.S. Air Force; and the Bureau of Medicine and Surgery, U.S. Navy. Resistance of Plasmodium falciparum to chloroquine has spread to most areas with malaria. Alternative drugs to chloroquine are either associated with adverse reactions, are of limited efficacy, or require complex and detailed instructions for use that reduce compliance. These factors have contributed to a threefold increase in the number of reported P. falciparum infections among U.S. travelers to malarious areas since 1980. A new drug, mefloquine (Lariam), is expected to be highly effective against both chloroquine-resistant and Fansidar-resistant P. falciparum infections. Mefloquine is now recommended as the drug of choice for travelers at risk of infection with chloroquine-resistant P. falciparum. Alternative drugs for travelers who cannot take mefloquine include 1) doxycycline alone or 2) chloroquine alone, with Fansidar available for standby treatment while medical care is sought for evaluation of febrile illness when travelers are in a malarious area. Prospective travelers and health-care providers are advised to call the CDC Malaria Hotline at (404) 332-4555 for detailed recommendations for the prevention of malaria.
Acid Rebound
Authors: John S. Fordtran
Journal: New England Journal of Medicine (1968)

A search for rebound gastric hypersecretion after ingestion of antacids in patients with duodenal ulcer revealed that aluminum-magnesium hydroxide (in a dose of 30 or 60 ml) and sodium bicarbonate (in a dose of 4 or 8 gm) failed to stimulate gastric secretion in the assay system used. By contrast, calcium carbonate (4 or 8 gm) induced gastric hypersecretion. Detailed studies in one patient suggest that the stimulatory effect of calcium carbonate is mediated by the action of calcium ions within the gastrointestinal tract and that this action is markedly potentiated by food. Although calcium carbonate therapy increases serum calcium concentration, the data suggest that hypercalcemia is not the mechanism by which this antacid stimulates gastric secretion.
Cognitive Effects of Endocrine-Disrupting Chemicals in Animals
Authors: Susan L. Schantz, John J. Widholm
Journal: Environmental Health Perspectives (2001)

A large number of chemical pollutants including phthalates, alkylphenolic compounds, polychlorinated biphenyls and polychlorinated dibenzodioxins, organochlorine pesticides, bisphenol A, and metals including lead, mercury, and cadmium have the ability to disrupt endocrine function in animals. Some of these same chemicals have been shown to alter cognitive function in animals and humans. Because hormonally mediated events play a central role in central nervous system development and function, a number of researchers have speculated that the changes in cognitive function are mediated by the endocrine-like actions of these chemicals. In this paper we review the evidence that cognitive effects of chemicals classified as environmental endocrine disruptors are mediated by changes in hormonal function. We begin by briefly reviewing the role of gonadal steroids, thyroid hormones, and glucocorticoids in brain development and brain function. We then review the endocrine changes and cognitive effects that have been reported for selected endocrine-disrupting chemicals, discuss the evidence for causal relationships between endocrine disruption and cognitive effects, and suggest directions for future research.
Ureteral Stone Management: I. Ureteroscopy and Extracorporeal Shock-Wave Lithotripsy
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Christian Science church loses first civil suit on wrongful death of a child
Authors: A. A. Skolnick
Journal: JAMA (1993)

IN THE FIRST verdict of its kind, a Minnesota jury on August 25 ordered the Christian Science church to pay $9 million in punitive damages for the death of a boy whose mother and stepfather withheld medical care in favor of Christian Science prayer. The boy, Ian Lundman, 11 years of age, died in 1989 of dehydration and ketoacidosis resulting from medically untreated diabetes. The Christian Science church instructs its followers to shun most medical care for themselves and their children and to rely on prayer instead, which it claims is more effective than medicine (<i>JAMA</i>. 1990;264:1379-1381). The Hennepin County jury's verdict came just a week after it awarded the boy's biological father, Douglas G. Lundman, and sister $5.2 million in compensatory damages for the wrongful death of the child. The jury found that the boy's mother and stepfather, Kathleen and William McKown, who are Christian Scientists; the First Church